coadministered cagrilintide and semaglutide in adults with overweight or obesity the REDEFINE 2 phase 3a trial involving diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Once-weekly cagrilintide for weight
Pay in 4 interest-free payments of $7.19 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
![coadministered cagrilintide and semaglutide in adults with overweight or obesity the REDEFINE 2 phase 3a trial involving diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Once-weekly cagrilintide for weight](https://figures.semanticscholar.org/a9800c8f0dc40d6d18a09ab6d2f14e71a42af380/9-Figure3-1.png)
![coadministered cagrilintide and semaglutide in adults with overweight or obesity the REDEFINE 2 phase 3a trial involving diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Once-weekly cagrilintide for weight](https://www.nejm.org/cms/asset/0e4b3922-625d-4a45-9015-1d254fd0598b/nejmoa2502082_f1.jpg)
![coadministered cagrilintide and semaglutide in adults with overweight or obesity the REDEFINE 2 phase 3a trial involving diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Once-weekly cagrilintide for weight](https://cdn.sanity.io/images/0vv8moc6/act/19850b926657eb8f808b66c896d1b92f14d84ca9-5945x3953.jpg)
![coadministered cagrilintide and semaglutide in adults with overweight or obesity the REDEFINE 2 phase 3a trial involving diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Once-weekly cagrilintide for weight](https://www.thelancet.com/cms/10.1016/S0140-6736(26)01022-6/asset/8e5594ca-57f9-4753-8b3e-9fa284427e35/main.assets/gr3_lrg.jpg)
![coadministered cagrilintide and semaglutide in adults with overweight or obesity the REDEFINE 2 phase 3a trial involving diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Once-weekly cagrilintide for weight](https://www.medicadepot.com/wp-content/uploads/2026/03/CagSem-10mg-Front.png.webp)
![coadministered cagrilintide and semaglutide in adults with overweight or obesity the REDEFINE 2 phase 3a trial involving diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Once-weekly cagrilintide for weight](https://cdn.prod.website-files.com/68072c16317fc2e0431a5348/69e147690e5668be0a17e1f4_CXR8c1QiNftPSsXIep15o_mcSKUTmu7o1zTXOMfvZ2Y.png)























